Hsiangkuo Yuan, MD
Neurology · Philadelphia, PANPI 1255711149
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,425 of the $44,351 with a category attached, or 75.4%. 25 manufacturers reported payments, led by Medical Device Business Services, Inc. at 40.9% of the total. 2025 is the largest year on record at $16,842, more than ten times the $868 reported in 2019.
Across 257 payments — averaging $172.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$18K
- Pfizer$17K
- AbbVie$4K
- Ipsen Innovation$1K
- Teva Pharmaceuticals USA, Inc.$942
- Amgen$490
- plus $2K from 19 others
Across 231 payments — averaging $1577.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Innovation$253K
- Pfizer$59K
- AbbVie$53K
What the payments were for
- Consulting fees$33,42575%
- Travel & lodging$3,4288%
- Food & beverage$7,40817%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 9 | $18,125 |
| Pfizer | 19 | $17,307 |
| AbbVie(2 entities) | 102 | $4,120 |
| Ipsen Innovation | 4 | $1,183 |
| Teva Pharmaceuticals USA, Inc. | 31 | $942 |
| Amgen | 15 | $490 |
| Lilly USA, LLC | 19 | $488 |
| Impel Pharmaceuticals Inc. | 14 | $482 |
| Axsome Therapeutics, Inc. | 5 | $192 |
| Upsher-smith Laboratories LLC | 9 | $172 |
| SPR Therapeutics, Inc | 2 | $154 |
| Lundbeck LLC | 7 | $153 |
| Argenx US, Inc. | 1 | $100 |
| Scilex Pharmaceuticals Inc. | 4 | $85 |
| Nevro Corp. | 1 | $64 |
| Eisai Inc. | 2 | $45 |
| Collegium Pharmaceutical, Inc. | 3 | $45 |
| Pfizer Corporation Hong Kong Limited | 2 | $43 |
| Novartis | 1 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Promius Pharma LLC | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,351 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 33 | $25,462 |
| Nurtec OdtRimegepant Sulfate | 12 | $24,775 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 33 | $23,882 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $20,848 |
| Emgality PenGalcanezumab-Gnlm | 21 | $15,020 |
| Ajovy SyringeFremanezumab-Vfrm | 11 | $7,933 |
| Candesartan Cilexetil | 21 | $1,636 |
| Sumatriptan Succinate | 17 | $1,417 |
| Mexiletine Hcl | 13 | $1,187 |
| Topiramate | 50 | $987 |
| Duloxetine Hcl | 19 | $375 |
| Amitriptyline Hcl | 26 | $333 |
| RizatriptanRizatriptan Benzoate | 44 | $312 |
| Dexamethasone | 23 | $158 |
| Ketorolac Tromethamine | 16 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $17,307 | $24,77512 claims |
| Upsher-smith Laboratories LLCTopiramate | $172 | $98750 claims |
| Lilly USA, LLCOlanzapine | $488 | $2411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.